Frontlight ResearchEarly access
Active, not recruitingPhase 2
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Key facts
- Who runs it
- Seattle Institute for Biomedical and Clinical Research
- Where
- Augusta, Boston, and Seattle, United StatesSee the 3 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 230 people, planned
- Started
- 12 Jan 2021
- Expected to end
- Nov 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- testosterone 1.62% gel
- placebo gel
- Record updated
- 6 July 2026
Who can take part
- Age
- 55 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Men with active solid or hematologic (blood) cancers who have received or are receiving chemo- and/or radiation therapy. Patients who have no evidence of disease (NED) for 60 months or less, which means that they are <60 months from their last treatment (chemotherapy and/or radiation therapy) will be included
- Age: 55 years and older
- Life expectancy of at least 6 months
- Serum testosterone, measured by mass spectrometry (gold standard method), of <348 ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range for total testosterone in healthy men is 348 ng/dL and the lower limits of free testosterone is <70 pg/ml in the Framingham Heart Study sample. As sex hormone binding globulin levels may be elevated in some men with cancer (resulting in elevation in total testosterone level), some of these symptomatic men may still be hypogonadal despite having total testosterone above this cut-off limit, but their free testosterone levels may still be below the lower limit of normal. Thus, men with free testosterone <70 pg/mL will be included
- Fatigue. Fatigue was selected as it is a highly prevalent symptom in cancer patients. Fatigue will be defined as a score on FACIT-Fatigue subscale of <40, which best divides cancer patients from the general population with accuracy
- Ability and willingness to provide informed consent
Who cannot take part
- Men with current or prior history of prostate, breast, testicular, or adrenal cancers
- Previous stroke with residual cognitive or functional deficits
- Uncontrolled congestive heart failure
- Myocardial infarction, acute coronary syndrome, revascularization surgery, stroke or thromboembolism (of any etiology) within 6 months
- Known history of thrombophilia due to a genetic mutation (e.g. Factor V Leiden)
- Bipolar disorder or schizophrenia
- Hematocrit >48%, serum creatinine >2.5 mg/dL
- Poorly controlled diabetes as defined by hemoglobin A1c >10.0%
- Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months
- PSA >4 ng/ml; nodule or induration on digital rectal exam
- Severe untreated sleep apnea
- Inability to provide informed consent; MMSE score <24
- Body mass index (BMI) >40 kg/m2
Where in United States
- Georgia Cancer Center at Augusta UniversityAugusta, United States
- Brigham and Women's HospitalBoston, United States
- Veterans Affairs Puget Sound Health Care SystemSeattle, United States
About the trial
What the trial wants to find out
This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.
The 2 groups in the trial
- testosterone 1.62% gelTreatment being tested
Testosterone 1.62% gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
- placebo gelPlacebo, for comparison
The placebo gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 July 2026